Heart failure & cardiomyopathies
Use of and Association Between Heart Failure Pharmacological Treatments and Outcomes in Obese Versus Non-Obese Patients with Heart Failure with Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry
Authors' conclusion
Obese patients were more likely to receive optimal treatments after adjustment for factors affecting tolerability, suggesting that perceived beyond actual tolerance issues limit GDMT implementation. RASi/ARNi and beta-blockers were associated with lower mortality regardless of obesity, with a greater association between RASi/ARNi and lower cardiovascular death in obese versus non-obese patients when considering competing risk.
Study context
- Population
- Patients with HFrEF in the Swedish Heart Failure (HF) Registry24% obese
- Participants
- 16,116 patients
- Exposure
- Obese vs non-obese patients with HFrEF
- Outcome
- Use of guideline-directed medical therapies (GDMT) and associated outcomes (all-cause/CV death, HF hospitalization)
Methodological detailsSwedish HF Registry, multivariable logistic and Cox regressions, competing risk analysis
- Swedish HF Registry
- Multivariable logistic and Cox regressions
- Competing risk analysis
Main finding
As reported in the abstract
Use of GDMT
RASi/ARNi
Beta-blockers
MRA
Observational data: associations, not effects.
Further findings
All-cause/CV death by treatment use
- Renin-angiotensin system inhibitors (RASi)/angiotensin receptor-neprilysin inhibitors (ARNi) and beta-blockers independently associated with lower risk of all-cause/CV death regardless of obesity (multivariable Cox)
- Competing risk analysis: lower risk of CV death with RASi/ARNi in obese vs non-obese
HF hospitalization by treatment use
- RASi/ARNi associated with lower risk in obese but not non-obese
- Beta-blockers not associated with risk regardless of obesity
- Competing risk analysis: RASi/ARNi associated with higher risk regardless of obesity
Original publication
Use of and Association Between Heart Failure Pharmacological Treatments and Outcomes in Obese Versus Non-Obese Patients with Heart Failure with Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. Published 6 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →